Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 Oct 25;105(9):1465-6; author's reply 1467.
doi: 10.1038/bjc.2011.412. Epub 2011 Oct 11.

Comment on 'Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab'

H Shimokawa, H Uramoto, F Tanaka
Comment

Comment on 'Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab'

H Shimokawa et al. Br J Cancer. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Comment on

References

    1. Baserga R (2007) Is cell size important? Cell Cycle 6: 814–816 - PubMed
    1. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM (2008) The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14: 6364–6370 - PubMed
    1. Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, Paz-Ares LG, Novello S, Blakely J, Langer CJ, Pollak MN (2011) Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 104: 68–74 - PMC - PubMed
    1. Mauro L, Bartucci M, Morelli C, Andò S, Surmacz E (2001) IGF-I receptor-induced cell-cell adhesion of MCF-7 breast cancer cells requires the expression of junction protein ZO-1. J Biol Chem 276: 39892–39897 - PubMed
    1. Nakagawa M, Uramoto H, Shimokawa H, Onitsuka T, Hanagiri T, Tanaka F (2011) Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung. Exp Ther Med 2: 585–590 - PMC - PubMed

MeSH terms

Substances